Clinical study of trimetazidine,telmisrtan and low molecular weight heparin in treatment of chronic pulmonary heart disease in acute exacerbation
10.3760/cma.j.issn.1673-4904.2009.34.003
- VernacularTitle:曲美他嗪、替米沙坦联合低分子肝素治疗慢性肺心病急性加重期的临床研究
- Author:
Yongliang PAN
;
Yanbin CHEN
;
Hui FAN
- Publication Type:Journal Article
- Keywords:
Trimetazidine;
Telmisartan;
Heparin;
low molecular weight;
Pulmonary heart disease
- From:
Chinese Journal of Postgraduates of Medicine
2009;32(34):9-12
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of trimetazidine, telmisartan and low molecular weight heparin (LMWH) on improving cardiopulmonary function, hemorheology and clinical symptom of chronic pulmonary heart disease in acute exacerbation. Methods A total of 96 patients with chronic pulmonary heart disease in acute exacerbation were randomly divided into group A (40 cases) and group B (56 cases ).The group A was treated with general method and the group B was treated with trimetazidine, telmisartan and LMWH besides general method. After 3 weeks' treatment, ca_rdiopulmonary functional parameters,hemorbeology parameters and clinical symptoms were observed. Results After treatment, the left ventricular ejection fraction (LVEF), and the ratio of forced expiratory volume in one second and forced vital capacity (FEV_1/FVC ) improved in group B (P<0.05 ), and there were significant difference in LVEF, FEV_1/FVC after treatment between two groups (P<0.05). The clinical total effective rate in group B (92.9%, 52/56 ) was significantly higher than that in group A (67.5%, 27/40 ) ( P<0.05 ). Conclusion Trimetazidine, telmisartan and LMWH is effective to improve patients' cardiopulmonary function, hemorheology parameters and clinical symptoms in the treatment of chronic pulmonary heart disease in acute exacerbation.
